Fulcrum Capital LLC Raises Holdings in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)

Fulcrum Capital LLC grew its position in shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) by 0.5% in the first quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 15,578 shares of the pharmaceutical company’s stock after purchasing an additional 84 shares during the period. Vertex Pharmaceuticals makes up approximately 1.7% of Fulcrum Capital LLC’s investment portfolio, making the stock its 20th biggest position. Fulcrum Capital LLC’s holdings in Vertex Pharmaceuticals were worth $7,553,000 at the end of the most recent reporting period.

A number of other institutional investors have also recently made changes to their positions in VRTX. Brown Lisle Cummings Inc. purchased a new position in Vertex Pharmaceuticals in the fourth quarter worth about $30,000. Mascagni Wealth Management Inc. purchased a new position in Vertex Pharmaceuticals in the fourth quarter worth about $31,000. Golden State Wealth Management LLC purchased a new position in Vertex Pharmaceuticals in the fourth quarter worth about $37,000. Truvestments Capital LLC grew its position in Vertex Pharmaceuticals by 30.3% in the fourth quarter. Truvestments Capital LLC now owns 99 shares of the pharmaceutical company’s stock worth $40,000 after acquiring an additional 23 shares in the last quarter. Finally, Mpwm Advisory Solutions LLC purchased a new position in Vertex Pharmaceuticals in the fourth quarter worth about $40,000. Hedge funds and other institutional investors own 90.96% of the company’s stock.

Vertex Pharmaceuticals Stock Down 0.9%

VRTX stock opened at $443.01 on Friday. The company has a market cap of $113.76 billion, a price-to-earnings ratio of -201.37, a PEG ratio of 2.11 and a beta of 0.51. The company has a current ratio of 2.69, a quick ratio of 2.35 and a debt-to-equity ratio of 0.01. Vertex Pharmaceuticals Incorporated has a 12 month low of $377.85 and a 12 month high of $519.88. The firm has a 50-day moving average of $469.67 and a two-hundred day moving average of $461.14.

Vertex Pharmaceuticals (NASDAQ:VRTX) last announced its quarterly earnings results on Monday, May 5th. The pharmaceutical company reported $4.06 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $4.29 by ($0.23). The firm had revenue of $2.77 billion for the quarter, compared to analyst estimates of $2.85 billion. Vertex Pharmaceuticals had a negative return on equity of 2.02% and a negative net margin of 4.86%. The firm’s quarterly revenue was up 2.6% on a year-over-year basis. During the same quarter in the prior year, the business earned $4.76 EPS. As a group, analysts forecast that Vertex Pharmaceuticals Incorporated will post 15.63 earnings per share for the current fiscal year.

Insider Transactions at Vertex Pharmaceuticals

In other news, EVP David Altshuler sold 3,231 shares of the firm’s stock in a transaction that occurred on Monday, March 10th. The shares were sold at an average price of $500.00, for a total transaction of $1,615,500.00. Following the completion of the sale, the executive vice president now owns 26,512 shares in the company, valued at $13,256,000. This trade represents a 10.86% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Insiders own 0.20% of the company’s stock.

Wall Street Analyst Weigh In

Several research analysts have issued reports on the company. Wolfe Research lowered Vertex Pharmaceuticals from an “outperform” rating to a “peer perform” rating in a research report on Wednesday, May 7th. Wall Street Zen raised shares of Vertex Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Tuesday, March 11th. Truist Financial lifted their price target on shares of Vertex Pharmaceuticals from $460.00 to $520.00 and gave the company a “buy” rating in a research note on Tuesday, February 11th. HC Wainwright reaffirmed a “buy” rating and set a $550.00 price target on shares of Vertex Pharmaceuticals in a research note on Tuesday, February 11th. Finally, Barclays lifted their price target on shares of Vertex Pharmaceuticals from $435.00 to $467.00 and gave the company an “equal weight” rating in a research note on Tuesday, February 11th. Fourteen investment analysts have rated the stock with a hold rating, sixteen have assigned a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $515.04.

Vertex Pharmaceuticals Profile

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.